Sonus Pharmaceuticals Inc: Premium Company Profile
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- Overview - page 1
- Catalyst - page 1
- Summary - page 1
- Table of Contents - page 2
- Table of figures - page 3
- Table of tables - page 4
- Company Structure - page 5
- Company Overview and Key Facts - page 5
- Business Description - page 6
- Landmark Products & Services - page 7
- TOCOSOL technology - page 7
- Landmark Products & Services - page 7
- History - page 8
- Locations and Subsidiaries - page 10
- Company Financials - page 11
- Stock Market Performance - page 11
- P&L - page 13
- Balance Sheet - page 16
- Cash Flow - page 16
- Business Segment Performance - page 17
- Products & Services - page 18
- Pipeline Products - page 18
- In-house Pipeline - page 18
- TOCOSOL Camptothecin - page 18
- In-house Pipeline - page 18
- Pipeline Products - page 18
- Competitors and Strategic Business Relationships - page 19
- Top Competitors - page 19
- Shareholding Structure - page 20
- Strategy - page 21
- Company View - page 21
- Corporate Strategy - page 23
- SWOT Analysis - page 24
- Overview - page 24
- Strengths - page 25
- TOCOSOL technology - page 25
- Weaknesses - page 26
- Termination of TOCOSOL Paclitaxel - page 26
- Opportunities - page 27
- TOCOSOL Camptothecin - page 27
- Anticancer drugs market - page 27
- Threats - page 28
- Early stage pipeline - page 28
- Industry consolidation - page 28
- Value Chain Analysis - page 29
- Overview - page 29
- Discovery and Product Development - page 30
- Key Employees - page 31
- List of Key Employees - page 31
- Key Employee Biographies - page 32
- Michael A. Martino - page 32
- Alan Fuhrman - page 32
- Robert E. Ivy - page 33
- Michelle Burris - page 33
- George W. Dunbar - page 34
- Dwight Winstead - page 34
- Richard Daifuku - page 35
- Elaine Waller - page 35
- Lynn Gold - page 35
- Neile A. Grayson - page 36
- Dean R. Kessler - page 36
- Ingrid Rasch - page 36
- Financial and Operational Overview - page 38
- Financial and Operational Overview - page 38
- Appendix - page 40
- Ask the analyst - page 40
- Datamonitor consulting - page 40
- Disclaimer - page 40
- List of Tables
- Table 1: Sonus - Key Facts - page 5
- Table 2: Sonus - Other Locations and Subsidiaries - page 10
- Table 3: Sonus - Year-End Share Price and Market Capitalization, 2002-2006 ($) - page 11
- Table 4: Sonus - Key Events Impacting Share Price Performance - page 12
- Table 5: Sonus - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 13
- Table 6: Sonus - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) - page 14
- Table 7: Sonus - Balance Sheet, 2002-2006 ($ Mn) - page 16
- Table 8: Sonus - Cash Flow, 2002-2006 ($ Mn) - page 16
- Table 9: Sonus - Revenue Breakdown, 2002-2006 ($ Mn) - page 17
- Table 10: Sonus - In-house Pipeline Products - page 18
- Table 11: Sonus - Top Competitors - page 19
- Table 12: Sonus - Key Shareholders - page 20
- Table 13: Sonus - SWOT Analysis Summary - page 24
- Table 14: Sonus - Value Chain Analysis - page 29
- Table 15: Sonus - Key Employees - page 31
- Table 16: Sonus - Financial and Operational Overview - page 38
- List of Figures
- Figure 1: Sonus - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 14
Other users found this report page using the following search terms: Sonus Pharmaceuticals sonus pharmaceuticals profile market pharmaceutical daifuku pipeline analysis sonuspharmaceuticals grayson
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.